Figure 9. A meta-analysis of cardiovascular events in randomized testosterone trials In this meta-analysis of cardiovascular-related events in randomized testosterone trials included 2,994 men from 27 eligible trials of 12 weeks or longer duration. Randomization to testosterone was associated with a significantly increased risk of cardiovascular-related event (odds ratio (OR) 1.54 (577). An additional finding of this meta-analysis was that the risk of a cardiovascular-related event on testosterone therapy was even greater (OR 2.06) in trials that were not funded by the pharmaceutical industry; in contrast, the trials funded by the pharmaceutical industry did not reveal a significant increase in cardiovascular events.
Reproduced with permission from Xu et al (577)